MedTrace Logo

Effects of Caffeine and Nicotine Gum on Balance Performance in Athletes

NCT07254832 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-04

No results posted yet for this study

Summary

This randomized, single-blind, placebo-controlled, four-condition crossover study evaluates the acute effects of caffeine gum (\~3 mg/kg) and nicotine gum (4 mg) on balance performance in healthy, trained adults. Each participant completes four test visits (caffeine gum, nicotine gum, xylitol-based placebo gum, and no-gum control) separated by ≥24 hours. Static and dynamic balance are assessed using the ProKin 252 system under standardized procedures. The primary outcomes are postural sway (ellipse area) and center-of-pressure path length over predefined test trials/time frames. The objective is to determine whether acute administration of these stimulants alters balance-related performance relative to placebo and control.

Conditions

  • Athletic Performance
  • Postural Stability
  • Healhty

Interventions

DIETARY_SUPPLEMENT

Caffeine Gum 3mg/kg

Participants chewed 2-3 pieces of 100 mg caffeine gum (\~3 mg/kg total) for 5 minutes prior to balance testing.

DIETARY_SUPPLEMENT

Nicotine Gum (4 mg)

Participants chewed one piece of 4 mg nicotine gum for 30 minutes before undergoing balance testing.

OTHER

Placebo Gum (Xylitol)

Participants chewed xylitol-based sugar-free gum with no active substance for 20 minutes prior to testing.

Sponsors & Collaborators

  • Gülbin Rudarlı

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-08
Primary Completion
2024-04-05
Completion
2024-07-02

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07254832 on ClinicalTrials.gov